Immune checkpoint blockade with therapeutic anti-cytotoxic T lymphocyte-associated antigen (CTLA)-4 (Ipilimumab) and anti-programmed death (PD)-1 (Nivolumab and Pembrolizumab) antibodies alone or in combination has shown remarkable efficacy in multiple cancer types. concomitant with immune-related adverse events. including arthralgia and inflammatory arthritis (IA) in some patients. H... https://www.hindigyanvishv.com/